Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Says to Publish PAFSC Minutes for COVID-19 Vaccines in 3 Weeks, but Opposition Parties Unimpressed
For COVID-19 vaccines, the Ministry of Health, Labor and Welfare (MHLW) plans to publish meeting minutes in “around three weeks” after they are discussed by its key advisory panel, officials told lawmakers on November 9, but opposition parties were still…
To read the full story
Related Article
- Japan Diet Clears Immunization Bill
December 2, 2020
- Japan Diet Expected to Enact Immunization Bill on Dec. 2
November 27, 2020
- Lower House Passes Immunization Act Amendment Bill
November 20, 2020
- Lower House Health Committee Starts Debate on Immunization Bill; Minister Says to Publish PAFSC Meeting Minutes ASAP
November 12, 2020
- PM Suga Vows Transparency in COVID-19 Vaccine Review as Immunization Bill Enters Diet Deliberations
November 11, 2020
- Swiftly Disclose PAFSC Minutes for COVID-19 Vaccines: Opposition Parties
November 9, 2020
REGULATORY
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
- Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
- Blister Pack Supplies Seen Returning to Normal: Health Minister
May 22, 2026
- LDP “Eto” Study Group Submits Honebuto Proposal to Health Minister
May 22, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…